Newsletter
One email. The theses worth reading.
Every issue collects the biotech arguments worth keeping from Reddit and X, checked against ClinicalTrials.gov, SEC EDGAR, Drugs@FDA and PubMed, with credit and a link to whoever made the case first. No more than one a week. Unsubscribe from any issue in one click.
Subscribe
You will get a confirmation link first, so nobody can sign you up.
BioCatalyst reports what public records say. It is not investment advice.